IQVIA Holdings Inc. (NYSE:IQV) Short Interest Up 11.0% in December

IQVIA Holdings Inc. (NYSE:IQV) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,120,000 shares, an increase of 11.0% from the December 15th total of 2,810,000 shares. Approximately 1.7% of the company’s shares are short sold. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 2.0 days.

IQVIA Stock Performance

Shares of IQV stock traded down $0.41 during trading on Monday, reaching $197.25. 1,253,280 shares of the company’s stock were exchanged, compared to its average volume of 1,057,891. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market capitalization of $35.80 billion, a PE ratio of 25.89, a PEG ratio of 2.09 and a beta of 1.48. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The firm’s fifty day moving average price is $200.09 and its 200-day moving average price is $221.39.

Analyst Ratings Changes

A number of analysts recently commented on IQV shares. JPMorgan Chase & Co. lowered their price objective on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Truist Financial decreased their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $255.82.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Private Trust Co. NA grew its holdings in IQVIA by 10.7% in the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after buying an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC grew its holdings in IQVIA by 1.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after buying an additional 50 shares in the last quarter. Pine Valley Investments Ltd Liability Co grew its holdings in IQVIA by 0.5% in the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after buying an additional 50 shares in the last quarter. Fortitude Family Office LLC grew its holdings in IQVIA by 2.9% in the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock valued at $468,000 after buying an additional 56 shares in the last quarter. Finally, Huntington National Bank grew its holdings in IQVIA by 7.4% in the 3rd quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock valued at $192,000 after buying an additional 56 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.